XTRA:MRK
XTRA:MRKPharmaceuticals

Merck KGaA (XTRA:MRK) Is Up 10.1% After Q3 Outperformance and Maintained Guidance Has The Bull Case Changed?

Merck KGaA recently reported third-quarter 2025 results, delivering sales of €5.32 billion and net income of €902 million, both modestly higher than the previous year. This performance was boosted by legislative changes in South America, the sale of a U.S. priority review voucher, and revenue contributions from recently acquired rare cancer treatments. We’ll assess how the outperformance in operating earnings and maintained guidance influences Merck KGaA’s investment narrative and future...
BME:TRE
BME:TREEnergy Services

Why Técnicas Reunidas (BME:TRE) Is Up 5.1% After Nine-Month Sales and Income Surge

Técnicas Reunidas, S.A. reported earnings for the nine months ended September 30, 2025, with sales rising to €4.60 billion and net income reaching €106.9 million, both up from the same period last year. This earnings report reflects improved business performance and financial health, as the company recorded higher sales, revenue, and net income year-over-year. We'll explore how Técnicas Reunidas' substantial year-on-year sales and income growth may influence its investment narrative and...
HLSE:ALMA
HLSE:ALMAMedia

Alma Media (HLSE:ALMA): Assessing Valuation After Q3 Earnings Growth and Transformation Progress

Alma Media Oyj (HLSE:ALMA) just released its third quarter and nine-month earnings, reporting higher sales and net income compared to last year. Investors are watching closely as the company continues its business transformation plans and growth initiatives. See our latest analysis for Alma Media Oyj. This latest update has kept Alma Media Oyj on investors’ radar, especially with management signaling more acquisitions and a push into new services. The stock’s momentum remains strong as its...
ASX:PME
ASX:PMEHealthcare Services

Pro Medicus (ASX:PME): How US Contract Momentum Shapes Its Current Valuation

Pro Medicus (ASX:PME) has made headlines by clinching three major US hospital contracts in just four months. This achievement has already tripled its contract win rate from last year and sparked fresh curiosity among investors. See our latest analysis for Pro Medicus. Despite some recent share price volatility, including a 10.98% dip over the past month, Pro Medicus is still up 24.96% on a total shareholder return basis for the past year and has delivered a remarkable 336% over three years...
WBAG:WIE
WBAG:WIEBasic Materials

Why Wienerberger (WBAG:WIE) Is Up 7.1% After Reporting Strong Sales and Surging Net Income

Wienerberger AG reported its earnings for the nine months ended September 30, 2025, revealing sales of €3.52 billion and net income of €171 million, both up year-over-year. This performance marks a very large increase in net income, highlighting improved operational efficiency and a shift in profitability within the company. We'll examine how Wienerberger's substantial earnings growth adds momentum to its investment narrative focused on margin improvement and sustainable expansion. Rare...
NasdaqCM:APPS
NasdaqCM:APPSSoftware

Digital Turbine (APPS) Valuation: Assessing Upside After Q2 Growth and Raised Outlook

Digital Turbine (APPS) just delivered its second-quarter 2026 results, showing improvements that caught the attention of many investors. The company posted an 18% boost in revenue and upgraded its full-year outlook, which suggests ongoing momentum. See our latest analysis for Digital Turbine. Despite Digital Turbine’s upbeat earnings and refreshed outlook, volatility has been intense lately. The past week alone saw a sharp 17% drop in share price, following a stellar year-to-date gain of...
NasdaqGS:VTRS
NasdaqGS:VTRSPharmaceuticals

Viatris (VTRS) Is Up 7.9% After Boosting 2025 Revenue Outlook and Reaffirming Dividend

Earlier this month, Viatris Inc. announced an increase in its full-year 2025 revenue guidance to a midpoint of US$14.1 billion, up from its previous midpoint of US$13.75 billion, while also outlining continued M&A ambitions and affirming a quarterly dividend of US$0.12 per share. This more optimistic outlook comes despite reporting a third-quarter net loss and declining revenue for the nine months ended September 30, 2025, suggesting management anticipates improvements ahead. We'll explore...